

1 AN ACT relating to medication-assisted therapy in community pharmacies.

2 *Be it enacted by the General Assembly of the Commonwealth of Kentucky:*

3 ➔SECTION 1. A NEW SECTION OF KRS CHAPTER 205 IS CREATED TO
4 READ AS FOLLOWS:

5 *(1) For the purposes of this section, "pilot program" means a program in a county*
6 *or set of counties, or a subset or subsets of the population, as designated by the*
7 *Cabinet for Health and Family Services and the Department for Behavioral*
8 *Health, Developmental and Intellectual Disabilities.*

9 *(2) A pilot program is established to analyze the outcomes and effectiveness of a*
10 *community pharmacy care delivery model for medication-assisted therapy for*
11 *treatment of substance abuse in order to ensure that the Commonwealth is:*

12 *(a) Using approaches that have been shown to be effective;*

13 *(b) Intervening early at important stages and transitions; and*

14 *(c) Intervening in appropriate settings and domains.*

15 *(3) Sources of data for the pilot program shall include, at a minimum, claims data*
16 *from the Department for Medicaid Services, including claims data from Medicaid*
17 *managed care organizations submitted to the Department for Medicaid Services.*

18 *(4) As funds are available, the Cabinet for Health and Family Services shall initiate*
19 *a pilot program to determine, collect, and analyze performance measurement*
20 *data for a community pharmacy care delivery model for medication-assisted*
21 *therapy as part of substance abuse treatment services to determine practices that*
22 *increase access to treatment, reduce frequency of relapse, provide better outcomes*
23 *for patients, and control health costs related to substance abuse treatment.*

24 *(a) Program components shall:*

25 *1. Use a community pharmacy care delivery model for medication-*
26 *assisted therapy for the treatment of substance abuse;*

27 *2. Include a wraparound services model that engages psychological and*

1 social support for the patient; and

2 3. Establish collaborative relationships between detention facilities, drug
3 courts, community pharmacists, and practitioners who provide
4 psychosocial interventions to evaluate individuals' eligibility for
5 participation in a community pharmacy care delivery model for
6 medication-assisted therapy.

7 (b) The Department for Medicaid Services shall pay any participating
8 community pharmacist for any medical services delivered specifically
9 related to medication-assisted therapy treatment program requirements at a
10 rate of eighty-five percent (85%) of the physician fee schedule for those
11 medical services.

12 (c) No prior authorizations shall be required for medication-assisted therapies
13 for community pharmacies as part of this pilot project.

14 (d) A pharmacy or pharmacist participating in this pilot project shall not be
15 barred, excluded, or have any other mandates, conditions, or restrictions
16 placed on it by any Medicaid managed care organization, or its contracted
17 pharmacy benefit manager, for participation in the pilot program
18 established in this section or from dispensing medications used in the
19 medication-assisted treatment program.

20 (5) By December 31, 2019, the Cabinet for Health and Family Services shall provide
21 a joint report to the Legislative Research Commission and the Office of the
22 Governor that:

23 (a) Details the findings of the pilot program; and

24 (b) Includes recommendations based on the pilot program's results for
25 optimizing substance abuse treatment services provided in community
26 pharmacies.